We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

By LabMedica International staff writers
Posted on 30 Apr 2025

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. More...

However, around 1 in 5 individuals with myeloma have a high-risk form of the disease, which is marked by an earlier relapse following initial treatment. This leads to a shorter survival period, typically just 2-3 years. A key challenge for clinicians is predicting when relapse will occur so that patients can be treated with effective alternative therapies before the disease advances. Now, a research team is evaluating a new mass spectrometry-based monitoring technique to determine its ability to predict and identify early relapses of the disease.

The introduction of more effective therapies over the past two decades has significantly improved survival rates for myeloma patients. The most recent generation of myeloma drugs includes therapeutic monoclonal antibodies (t-mAb), which have shown remarkable efficacy. However, these drugs can interfere with traditional electrophoretic methods used to measure the patient’s monoclonal immunoglobulin (M-Ig), making patient monitoring more challenging. Therefore, alternative laboratory methods that address the limitations of these conventional approaches are needed. Oxford University Hospitals (Oxford, UK), in collaboration with other institutions, is leading the investigation into a new monitoring method known as quantitative immunoprecipitation-mass spectrometry (QIP-MS). The research team will assess whether QIP-MS can predict and detect relapse earlier than current methods in patients with high-risk myeloma participating in the Myeloma XV RADAR trial. This trial involves analyzing bone marrow samples to determine the most effective treatments for myeloma and aims to measure small amounts of myeloma cells, referred to as minimal residual disease (MRD), that may persist after initial treatment.

Previous research has shown that QIP-MS is clinically useful as a first-line screening tool for investigating monoclonal gammopathy, offering higher sensitivity and resolution than the standard methods currently in use. Serum or urine protein electrophoresis (SPEP or UPEP) and immunofixation electrophoresis (SIFE or UIFE) are commonly used to detect M-proteins in multiple myeloma patients. However, SPEP and SIFE are not sufficiently sensitive to detect low levels of M-proteins, which may still be clinically significant. QIP-MS, on the other hand, allows for the identification of M-proteins in patients with multiple myeloma who are otherwise in complete remission, and could be ideal for evaluating MRD in peripheral blood. One significant advantage of QIP-MS is that it uses blood samples rather than bone marrow, which, if proven to be more sensitive, would reduce the need for painful procedures during regular monitoring for patients.


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Hematology Analyzer
Medonic M32B
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A simple blood sample that allows DNA methylation could identify epigenetic biomarkers (Photo courtesy of 123RF)

Simple Blood Sample Could Identify Epigenetic Biomarkers to Predict CVD Risk in Type 2 Diabetes

People with type 2 diabetes face up to four times higher risk of cardiovascular events such as heart attacks, strokes, and angina compared to individuals without the condition. Yet, current tools used... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The new technology could predict who will benefit from immunotherapy (Photo courtesy of Max Delbrück Center)

New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response

A healthy immune system depends on complex communication between specialized cell types that detect, alert, and eliminate harmful threats. When these immune signaling pathways break down, the result can... Read more

Microbiology

view channel
Image: MycoMEIA Aspergillus Assay is the first FDA-cleared urine-based test for invasive aspergillosis (Photo courtesy of Pearl Diagnostics)

Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People

Invasive Aspergillosis (IA), a life-threatening fungal infection, poses a serious threat to immunocompromised individuals, especially those with hematologic malignancies, transplants, or severe lung diseases.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.